TRAW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Traws Pharma Inc (TRAW) is not a good buy at this moment for a beginner investor with a long-term strategy. The company is facing severe financial challenges, with revenue and net income dropping significantly in the latest quarter. Additionally, technical indicators suggest a bearish trend, and there are no recent positive catalysts or strong trading signals to support a buy decision.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is at 31.49, which is neutral but close to oversold territory. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 1.34 and the current pre-market price at 1.22, suggesting further downside risk.
Ladenburg initiated coverage with a Buy rating and a $6.50 price target, citing the company's alternative to Cidara's CD388.
No recent news or significant trading trends from hedge funds or insiders. Financials show a complete revenue drop (-100% YoY) and worsening net income (-106.59% YoY). Technical indicators are bearish, and there are no recent Congress trades or influential figure activity.
In 2025/Q4, revenue dropped to 0 (-100% YoY), net income fell to -$5,398,000 (-106.59% YoY), and EPS declined to -0.34 (-101.28% YoY). Despite a gross margin increase to 100%, the company's financial health is severely deteriorating.
Ladenburg initiated coverage with a Buy rating and a $6.50 price target, but this is the only analyst rating available. The price target is significantly higher than the current price, but the lack of other ratings and the company's poor financial performance reduce the reliability of this recommendation.
